Nifty
Sensex
:
:
25178.65
81287.19
-317.90 (-1.25%)
-961.42 (-1.17%)

Pharmaceuticals & Drugs - Domestic

Rating :
65/99

BSE: 500488 | NSE: ABBOTINDIA

26530.00
27-Feb-2026
  • Open
  • High
  • Low
  • Previous Close
  •  26410
  •  26595
  •  26075
  •  26355.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  7169
  •  189312185
  •  37000
  •  26075

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 56,300.34
  • 36.94
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 55,021.09
  • 1.79%
  • 12.83

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.99%
  • 0.71%
  • 13.42%
  • FII
  • DII
  • Others
  • 0.19%
  • 8.71%
  • 1.98%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.38
  • 8.26
  • 6.21

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.62
  • 12.99
  • 7.02

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.68
  • 15.41
  • 14.21

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 48.48
  • 48.86
  • 47.79

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.08
  • 15.28
  • 15.70

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.90
  • 32.85
  • 32.45

Earnings Forecasts:

(Updated: 28-02-2026)
Description
2024
2025
2026
2027
Adj EPS
665.62
733.04
820.04
915.54
P/E Ratio
39.86
36.19
32.35
28.98
Revenue
6409.15
6940.87
7542.54
8225.59
EBITDA
1694.6
1895.71
2132.83
2372.01
Net Income
1414.44
1557.67
1742.56
1945.5
ROA
25.46
25.65
26.2
25.99
P/B Ratio
13.32
12.26
10.52
9.03
ROE
35.66
34.94
34.46
33.44
FCFF
1084.61
1296.33
1584.59
1761.43
FCFF Yield
1.98
2.37
2.9
3.22
Net Debt
-1431.25
-1757.45
-2186.2
-2702.25
BVPS
1992.14
2164.35
2521.22
2936.51

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Expenses
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBITDA
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Interest
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Depreciation
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PBT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Nov 01
Net Sales
-
356.31
Net Sales Growth
-
 
Cost Of Goods Sold
-
182.40
Gross Profit
-
173.91
GP Margin
-
48.81%
Total Expenditure
-
305.87
Power & Fuel Cost
-
2.92
% Of Sales
-
0.82%
Employee Cost
-
21.63
% Of Sales
-
6.07%
Manufacturing Exp.
-
16.42
% Of Sales
-
4.61%
General & Admin Exp.
-
9.79
% Of Sales
-
2.75%
Selling & Distn. Exp.
-
63.11
% Of Sales
-
17.71%
Miscellaneous Exp.
-
9.59
% Of Sales
-
2.69%
EBITDA
-
50.44
EBITDA Margin
-
14.16%
Other Income
-
20.48
Interest
-
0.12
Depreciation
-
4.48
PBT
-
66.33
Tax
-
16.67
Tax Rate
-
25.13%
PAT
-
49.66
PAT before Minority Interest
-
49.66
Minority Interest
-
0.00
PAT Margin
-
13.94%
PAT Growth
-
 
EPS
-
23.42

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update:


  • Abbott India inks pact with Novo Nordisk India to launch Extensior
    27th Feb 2026, 16:00 PM

    Extensior is a second brand of Ozempic, the world’s most prescribed GLP-1 RA molecule

    Read More
  • Abbott India - Quarterly Results
    13th Feb 2026, 00:00 AM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.